SpecificiT Pharma

SpecificiT Pharma

Pioneering personalized cancer therapies with a novel approach using Minor Histocompatibility Antigens to target hematological cancers.

Founded 2016 0-1 employees Seed Biotechnology, Health Care +1

SpecificiT Pharma is a pioneering biopharmaceutical company founded in 2016 with a focus on creating innovative personalized cancer immunotherapies. The company's mission is to target hematological cancers using a novel approach that involves the utilization of Minor Histocompatibility Antigens (MiHAs), thereby enabling the donor T-cells to be safely directed towards eradicating cancer cells in patients. This distinctive method provides a valuable alternative for addressing hematological cancers, which are currently not effectively targeted by chimeric antigen receptor modified T cells (CAR-T) therapies. The last investment round for SpecificiT Pharma took place on 11 September 2017, where the company secured seed funding from notable investors including Amorchem, Sanderling Ventures, and Accel-Rx Health Sciences Accelerator. This financial backing signifies the confidence and support of key players in the biotechnology and pharmaceutical industries for the company's pioneering approach to cancer treatment. With its focus on biotechnology, health care, and the pharmaceutical sector, SpecificiT Pharma is positioned to make significant advancements in the field of personalized cancer therapies, addressing an unmet need in the treatment of hematological cancers. The company's dedication to innovation and novel approaches in cancer immunotherapy makes it a compelling opportunity for investors looking to support groundbreaking advancements in the healthcare industry.

Funding Stage	Amount	Investors	Lead Investors	Date
Seed Round	Undisclosed	3	Amorchem, Sanderling Ventures +1	11 Sep 2017

Funding Stage

Amount

Investors

Lead Investors

Date

Seed Round

Undisclosed

Amorchem, Sanderling Ventures +1

11 Sep 2017

FAQ About SpecificiT Pharma

Pioneering personalized cancer therapies with a novel approach using Minor Histocompatibility Antigens to target hematological cancers.

SpecificiT Pharma was founded in 2016.

SpecificiT Pharma operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Personalized medicine, Immunotherapy, Cancer treatment and Cell therapy.

SpecificiT Pharma has approximately 0-1 employees.

SpecificiT Pharma has completed 1 funding round. The latest funding stage is Seed.

Top alternatives and competitors to SpecificiT Pharma include Prescient Therapeutics, Leucid Bio, Autolus Therapeutics, ImmuneBridge, Rebirthel Co.,Ltd.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

SpecificiT Pharma and Prescient Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About SpecificiT Pharma

Funding Rounds & Investors (1)

SpecificiT Pharma Alternatives & Competitors

FAQ About SpecificiT Pharma